Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Eqrx Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2020
Status: Acquired
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Jan 13, 2025
Deals
Quick exit for Idrx shareholders as GSK pays $1B to get GIST asset
Early clinical data show efficacy signals that appear to improve on existing therapies in GI cancer settings
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Sep 17, 2024
Management Tracks
Peter Maag resigns as Kyverna CEO
Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more
BioCentury | Jul 10, 2024
Management Tracks
Promotions for Flagship’s Afzelius, Biondi come amid $3.6B raise
Plus: EveryONE names CEO and chairman and updates from Lunit, Quell, ImCheck, Aktis, Immunic and Curve
BioCentury | Mar 9, 2024
Finance
Public equity report: Boundless to test IPO appetite as follow-ons continue to deliver
Public offerings by Akero, BridgeBio, RegenxBio, Apogee, plus PIPEs for Ventyx and BiomX-Adaptive Phage union
BioCentury | Jan 23, 2024
Politics, Policy & Law
How Arnold Ventures paved the road to the IRA
And what the biopharma industry’s most effective critic wants to do next
BioCentury | Nov 17, 2023
Management Tracks
Memo names Erik van den Berg as CEO
Plus: Martin Murphy stepping down as Syncona chair, and updates from Red Tree, OMass and Anagenex
BioCentury | Oct 27, 2023
Management Tracks
Guerard succeeds Baldwin as Opthea’s CEO
Plus: Montai hires its first CMO and an update from Resilience
BioCentury | Oct 23, 2023
Deals
Oct. 23 Quick Takes: Merck drops two Kelun ADCs
Plus: FDA guidance facilitates communication about off-label uses and updates from Verve, Celltrion, Sanofi, Regeneron, Revolution, Harpoon, Aligos
Items per page:
1 - 10 of 68